CYCLERION THERAPEUTICS, INC. Earnings Per Share, Basic and Diluted
CYCLERION THERAPEUTICS, INC. (CYCN) reported Earnings Per Share, Basic and Diluted of -$0.30 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-04.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-04
- CYCLERION THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.30.
- CYCLERION THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.25.
- CYCLERION THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.26.
- CYCLERION THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.45.
- CYCLERION THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2021 was -$1.32.
- CYCLERION THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2020 was -$2.56.
- CYCLERION THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2019 was -$4.49.
- CYCLERION THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2018 was -$4.21.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.30 10-Q · filed 2022-05-04 | -$0.55 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$0.81 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$1.24 derived: net income ÷ weighted average shares · filed 2023-11-13 |
| 2021-12-31 | -$0.25 derived: net income ÷ weighted average shares · filed 2023-03-22 | -$0.51 derived: net income ÷ weighted average shares · filed 2023-03-22 | -$0.94 derived: net income ÷ weighted average shares · filed 2023-03-22 | -$1.32 10-K · filed 2022-02-24 |
| 2021-09-30 | -$0.26 10-Q · filed 2021-11-09 | -$0.70 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$1.08 10-Q · filed 2021-11-09 | -$1.46 derived: net income ÷ weighted average shares · filed 2023-05-12 |
| 2021-06-30 | -$0.45 10-Q · filed 2021-07-29 | -$0.85 10-Q · filed 2021-07-29 | -$1.22 derived: net income ÷ weighted average shares · filed 2023-05-12 | -$1.80 derived: net income ÷ weighted average shares · filed 2023-05-12 |
| 2021-03-31 | -$0.39 10-Q · filed 2022-05-04 | -$0.77 derived: net income ÷ weighted average shares · filed 2023-05-12 | -$1.35 derived: net income ÷ weighted average shares · filed 2023-05-12 | -$2.02 derived: net income ÷ weighted average shares · filed 2023-05-12 |
| 2020-12-31 | -$0.57 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$1.15 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$1.84 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$2.56 10-K · filed 2022-02-24 |
| 2020-09-30 | -$0.59 10-Q · filed 2021-11-09 | -$1.28 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$2.01 10-Q · filed 2021-11-09 | -$2.95 derived: net income ÷ weighted average shares · filed 2021-11-09 |
| 2020-06-30 | -$0.70 10-Q · filed 2021-07-29 | -$1.43 10-Q · filed 2021-07-29 | -$2.38 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$3.38 derived: net income ÷ weighted average shares · filed 2021-11-09 |
| 2020-03-31 | -$0.73 10-Q · filed 2021-04-30 | -$1.68 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$2.68 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$3.85 derived: net income ÷ weighted average shares · filed 2021-11-09 |
| 2019-12-31 | -$0.95 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$1.95 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$3.12 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$4.49 10-K · filed 2021-02-25 |
| 2019-09-30 | -$1.00 10-Q · filed 2020-11-05 | -$2.17 derived: net income ÷ weighted average shares · filed 2020-11-05 | -$3.54 10-Q · filed 2020-11-05 | -$9.32 derived: net income ÷ weighted average shares · filed 2020-11-05 |
| 2019-06-30 | -$1.18 10-Q · filed 2020-08-03 | -$2.54 10-Q · filed 2020-08-03 | -$10.99 derived: net income ÷ weighted average shares · filed 2020-11-05 | -$18.90 derived: net income ÷ weighted average shares · filed 2020-11-05 |
| 2019-03-31 | -$1.37 10-Q · filed 2020-05-04 | -$2493.90 derived: net income ÷ weighted average shares · filed 2020-11-05 | -$3563.51 derived: net income ÷ weighted average shares · filed 2020-11-05 | -$4651.21 derived: net income ÷ weighted average shares · filed 2020-11-05 |
| 2018-12-31 | -$1128.63 derived: net income ÷ weighted average shares · filed 2020-03-12 | -$2198.25 derived: net income ÷ weighted average shares · filed 2020-03-12 | -$3285.94 derived: net income ÷ weighted average shares · filed 2020-03-12 | -$4.21 10-K · filed 2020-03-12 |
| 2018-09-30 | -$1.07 10-Q · filed 2019-11-12 | -$2157.30 derived: net income ÷ weighted average shares · filed 2019-11-12 | -$3.08 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$1.09 10-Q · filed 2019-08-12 | -$2.01 10-Q · filed 2019-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |